Enterotoxin‐related genes PPFIA4 and SCN3B promote colorectal cancer development and progression

To identify the role of enterotoxin‐related genes in colorectal cancer (CRC) development and progression. Upregulated differentially expressed genes shared by three out of five Gene Expression Omnibus (GEO) data sets were included to screen the key enterotoxin‐induced oncogenes (EIOGs) according to criteria oncogene definition, enrichment, and protein–protein interaction (PPI) network analysis, followed by prognosis survival, immune infiltration, and protential drugs analyses was performed via integration of RNA‐sequencing data and The Cancer Genome Atlas‐derived clinical profiles. We screened nine common key EIOGs from at least three GEO data sets. A Cox proportional hazards regression models verified that more alive cases, decreased overall survival, and highest 4‐year survival prediction in CRC patients with high‐risk score. Protein tyrosine phosphatase receptor type F polypeptide‐interacting protein alpha‐4 (PPFIA4), STY11, SCN3B, and SPTBN5 were shared in the same PPI network. Immune infiltration results showed that SCN3B and synaptotagmin 11 expression were obviously associated with B cell, macrophage, myeloid dendritic cell, neutrophils, and T cell CD4+ and CD8+ in both colon adenocarcinoma and rectal adenocarcinoma. CHIR‐99021, MLN4924, and YK4‐279 were identified as the potential drugs for treatment. Finally, upregulated EIOGs genes PPFIA4 and SCN3B were found in colon adenocarcinoma and PPFIA4 and SCN3B were proved to promote cell proliferation and migration in vitro. We demonstrated here that EIOGs promoting a malignancy phenotype was related with poor survival and prognosis in CRC, which might be served as novel therapeutic targets in CRC management. Enterotoxin‐induced oncogenes (EIOGs) promoting a malignancy phenotype was related with poor survival and prognosis in colorectal cancer, the key EIOGs protein tyrosine phosphatase receptor type F polypeptide‐interacting protein alpha‐4 (PPPFIA4) and SCN3B, which upregulate in colon adenocarcinoma, can promote cell proliferation, migration and invasion in vitro. This study suggest that EIOGs might be served as novel therapeutic targets in colorectal cancer management.